To the Editor, Contemporary management of atrial fibrillation (AF) focuses on effective thromboprophylaxis with either direct oral anticoagulants (DOACs) or vitamin K antagonists (VKAs; e.g., warfarin/ acenocoumarol). Although DOACs offer a viable alternative, the majority of patients continue to receive VKAs. The quality of VKA therapy is determined by the proportion of time spent in the target range (TTR) of the international normalized ratio (INR, 2.0-3.0). The greatest benefit with VKAs is derived with TTR of ≥70% (1), whereas a low TTR predisposes to adverse outcomes (2) .
Obtaining a stabile INR that corresponds to TTR of ≥70% is often challenging owing to social, clinical, and behavioral influences. The SAMe-TT 2 R 2 score (Sex, female; Age, <60 years; >2 medical comorbidities; amiodarone treatment; tobacco smoking; race, non-white) has been recently proposed to facilitate the differentiation of patients who are expected to achieve stable anticoagulation (i.e., SAMe-TT 2 R 2 score of ≥2) from those who are at a risk for labile INR (3). However, beyond clinical and social aspects, behavioral factors pertaining to the patients' comprehension and acceptance of the complex requirements of VKA therapy could also affect treatment quality (4) .
We report the results of a survey that assessed the knowledge and expectations regarding VKA treatment in a cohort of patients with non-valvular AF (n=416; mean age, 65.1±9.9 years; 63.7% males) and the influence of the investigated behavioral factors on the quality of anticoagulation, as determined by 1-year TTR. An optimal anticoagulation was defined as 1-year TTR of ≥70%.
Regarding VKA-related knowledge, 98.1% of patients properly identified AF as an anticoagulation indication, and 97.3% pro-vided the brand name of their VKA medication, which might bear significance for emergency situations. Conversely, only 68.1% correctly identified an INR target range and 13.9% were unaware regarding the requirement for long-term anticoagulation persistence. Similar knowledge gaps were previously described with respect to poor quality anticoagulation and unwarranted treatment discontinuation, potentially leading to serious complications (5). Concerning satisfaction with VKAs, 77.6% of patients had a positive perception regarding VKA-related influence on the quality of life (QoL), whereas 74.7% expressed a positive attitude to QoL improvement with an improved VKA management.
Importantly, on multivariate analysis adjusted for the SAMe-TT 2 R 2 score, we demonstrated an independent association of patients' knowledge [correct identification of INR target range; odds ratio (OR), 1.66; 95% confidence interval (CI), 1.11-2.71], patients' satisfaction with VKAs [positive perception of VKA-related impact on QoL (OR, 3.50; 95% CI, 2.06-5.95), and a positive attitude to QoL improvement with an improved VKA management (OR, 1.54; 95% CI, 1.13-2.08)] with stable INR control, defined as 1-year TTR of ≥70%. A positive perception of VKA-related impact on QoL improved discrimination for optimal INR control (ΔC-statistic, 0.043; 95% CI, 0.014-0.072; p=0.004) compared with risk stratification using the SAMe-TT 2 R 2 score.
In conclusion, our results support the practical relevance of patient education to improve the quality of and compliance with VKAs and lend support to the significance of behavioral influences on treatment quality in clinical practice. Nevertheless, behavioral factors are inherently complex and unlikely to become a part of a practical risk stratification tool. The decisions on anticoagulation modality (VKAs vs. DOACs) should be essentially based on clinical risk assessment (e.g., SAMe-TT 2 R 2 score), but patients' perspectives deserve a close consideration to attain a positive attitude, hopefully translating to a greater treatment success. 
